Literature DB >> 20140904

Complement C5a regulates IL-17 by affecting the crosstalk between DC and gammadelta T cells in CLP-induced sepsis.

Ruonan Xu1, Renxi Wang, Gencheng Han, Jianan Wang, Guojiang Chen, Liyan Wang, Xia Li, Renfeng Guo, Beifen Shen, Yan Li.   

Abstract

Complement 5a (C5a) and Interleukin-17 (IL-17) are two important inflammatory mediators in sepsis. Here we studied the mechanisms underlying regulation of IL-17 by anaphylatoxin C5a. We found that C5a blockade increased the survival rate of mice following cecal ligation and puncture (CLP)-induced sepsis and decreased IL-17 expression in vivo. IL-17 was secreted mainly by gammadelta T cells in this model. Importantly, our data suggest that C5a participates in the regulation of IL-17 secretion by gammadelta T cells. Dendritic cells (DC) were found to act as a "bridge" between C5a and gammadelta T cells in a mechanism involving IL-6 and transforming growth factor beta (TGF-beta). These results imply that C5a affects the crosstalk between DC and gammadelta T cells during sepsis development, and this may result in a large production of inflammatory mediators such as IL-17.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20140904     DOI: 10.1002/eji.200940015

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  18 in total

1.  C5a regulates NKT and NK cell functions in sepsis.

Authors:  Michael E Fusakio; Javid P Mohammed; Yves Laumonnier; Kasper Hoebe; Jörg Köhl; Jochen Mattner
Journal:  J Immunol       Date:  2011-11-04       Impact factor: 5.422

2.  γδT-cell function in sepsis is modulated by C5a receptor signalling.

Authors:  Gencheng Han; Shaoxia Geng; Yurong Li; Guojiang Chen; Renxi Wang; Xinying Li; Yuanfang Ma; Beifen Shen; Yan Li
Journal:  Immunology       Date:  2011-04-19       Impact factor: 7.397

Review 3.  γδ T Cells and dendritic cells in refractory Lyme arthritis.

Authors:  Ali Divan; Ralph C Budd; Richard P Tobin; M Karen Newell-Rogers
Journal:  J Leukoc Biol       Date:  2015-01-20       Impact factor: 4.962

4.  Genetic and intervention studies implicating complement C3 as a major target for the treatment of periodontitis.

Authors:  Tomoki Maekawa; Toshiharu Abe; Evlambia Hajishengallis; Kavita B Hosur; Robert A DeAngelis; Daniel Ricklin; John D Lambris; George Hajishengallis
Journal:  J Immunol       Date:  2014-05-07       Impact factor: 5.422

Review 5.  Basic biology and role of interleukin-17 in immunity and inflammation.

Authors:  Camille Zenobia; George Hajishengallis
Journal:  Periodontol 2000       Date:  2015-10       Impact factor: 7.589

6.  Differential alterations of tissue T-cell subsets after sepsis.

Authors:  Archna Sharma; Weng-Lang Yang; Shingo Matsuo; Ping Wang
Journal:  Immunol Lett       Date:  2015-09-08       Impact factor: 3.685

7.  Elevated expression of IL-23/IL-17 pathway-related mediators correlates with exacerbation of pulmonary inflammation during polymicrobial sepsis.

Authors:  David M Cauvi; Michael R Williams; Jose A Bermudez; Gabrielle Armijo; Antonio De Maio
Journal:  Shock       Date:  2014-09       Impact factor: 3.454

8.  Complement component C5a promotes expression of IL-22 and IL-17 from human T cells and its implication in age-related macular degeneration.

Authors:  Baoying Liu; Lai Wei; Catherine Meyerle; Jingsheng Tuo; H Nida Sen; Zhiyu Li; Sagarika Chakrabarty; Elvira Agron; Chi-Chao Chan; Michael L Klein; Emily Chew; Frederick Ferris; Robert B Nussenblatt
Journal:  J Transl Med       Date:  2011-07-15       Impact factor: 5.531

9.  Murine IL-17+ Vγ4 T lymphocytes accumulate in the lungs and play a protective role during severe sepsis.

Authors:  Maria Fernanda de Souza Costa; Catarina Bastos Trigo de Negreiros; Victor Ugarte Bornstein; Richard Hemmi Valente; José Mengel; Maria das Graças Henriques; Claudia Farias Benjamim; Carmen Penido
Journal:  BMC Immunol       Date:  2015-06-03       Impact factor: 3.615

10.  Regulatory effects of C5a on IL-17A, IL-17F, and IL-23.

Authors:  Jamison J Grailer; Markus Bosmann; Peter A Ward
Journal:  Front Immunol       Date:  2013-01-09       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.